A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY
| Title | A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY |
|---|---|
| Description | This study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumabcompared with placebo in patients with high-risk MIBC who are ctDNA positive following cystectomy. Publish the data of MRD ctDNA-negative patients. |
| Organism | Homo sapiens |
| Data Type | Other Type of Genomic Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA023471 |
| Release Date | 2024-04-09 |
| Submitter | Dingwei Ye (fuscc2012@163.com) |
| Organization | Fudan University Shanghai Cancer Center |
| Submission Date | 2024-02-05 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005811-01 | MRD ctDNA - Negative | 19 | Other Type of Genomic Data | 11.6 KB | xlsx | 0 | Unavailable |